AGNC offers substantial monthly dividend income and potential upside from tighter mortgage spreads, but leveraged book-value losses, narrow payout coverage, and a premium to tangible equity undermine its current risk-reward profile.
Sell-rated reports
287 tickers rated SellRelay Therapeutics has a differentiated precision-oncology pipeline and substantial clinical upside, but its precommercial economics, dilution and demanding valuation make future shareholder returns highly dependent on successful trials.
Hut 8 offers substantial long-term AI data center growth potential through contracted power infrastructure, but negative free cash flow, complex project financing, and demanding execution requirements weaken the investment case.
Cipher Digital has significant long-term AI data center growth potential through contracted hyperscale infrastructure, but negative cash flow, heavy project financing and shareholder dilution currently undermine its investment appeal.
Uranium Energy offers scarce U.S. uranium assets and rapidly accelerating production, but extreme revenue multiples, negative free cash flow and persistent dilution require far more execution than current fundamentals support.
SELLAS is a high-risk oncology binary bet on a potentially curative AML vaccine and a promising CDK9 inhibitor, but heavy recent dilution and a $3.12 billion valuation priced for perfection argue for avoiding the downside risk.
Dianthus Therapeutics offers meaningful upside through differentiated autoimmune therapies and a well-funded late-stage pipeline, but its high valuation, unproven commercial model, and substantial dilution create an unfavorable risk-reward profile.
GRAIL offers substantial long-term growth potential through Galleri's multi-cancer screening technology and pending FDA approval, but weak operating economics, persistent cash burn, dilution, and demanding valuation undermine its current risk-reward profile.
Aurora could become a leading autonomous trucking platform as driverless fleets scale, but its extreme valuation relative to revenue, persistent cash burn, and shareholder dilution make execution risk substantial.
Erasca's promising pan-RAS oncology pipeline and substantial cash reserves create significant clinical upside, but its unproven commercialization, elevated valuation, and shareholder dilution make the investment highly speculative.
MARA's extensive power portfolio and emerging AI infrastructure contracts offer long-term growth optionality, but declining mining revenue, persistent cash burn, and uncertain project economics undermine its investment appeal.
Spyre Therapeutics offers substantial long-term potential through differentiated immunology combinations and strong liquidity, but unproven commercial economics, dilution, and demanding clinical expectations create significant investment risk.